The accompanying schedules include additional details on sales performance by geographic segment and GBU. $1.3 billion. Information regarding Baxter’s recent announcements, upcoming & past events, and other useful resources for investors. Try zooming out to include more results. For first-quarter 2020: The company expects sales growth of 4% to 5% on a reported basis and 5% to 6% on both a constant currency and operational basis. Baxter's Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year. "Our investigation of this matter as it relates to its financial impacts is now complete," said Mr. Almeida. Published. Baxter Reports Fourth-Quarter and Full-Year 2019 Results, Completes Financial Restatement Process, 2019 Fourth-Quarter and Full-Year Financial Schedules, Advancing American Kidney Health Initiative (AAKHI), partnership with COSMED srl to commercialize Q-NRG+, Initiated strategic planning in support of the, Broadened its injectable pharmaceuticals portfolio with the U.S. launch of, Announced U.S. Food and Drug Administration (FDA) approval for faster preparation of. Baxter annual revenue for 2018 was $11.099B, a 4.87% increase from 2017. This. Baxter International Inc. BAX reported fourth-quarter 2018 adjusted earnings of 78 cents per share, which surpassed the Zacks Consensus Estimate of. Zacks. "The relevant foreign exchange gains and losses were non-operational in nature, and our core operational performance across this period continues to demonstrate the strength and trajectory of our ongoing transformation, fueled by revitalized innovation, increased efficiency and the dedication of our 50,000 employees worldwide.". Pioneering innovation in hemodialysis and peritoneal dialysis to help you achieve better outcomes for your patients. — Baxter International Inc. reported Q4 2019 earnings of $0.97 per share, up 37% from last year. Express, Inc. (NYSE:EXPR) Q4 2019 Earnings Conference Call. In 2019, Baxter achieved many milestones in pursuit of its Mission for patients and emphasis on accelerating profitable ... Q4 2019. BAXTER INTERNATIONAL INC. A webcast of Baxter's fourth-quarter 2019 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CST on March 17, 2020. This press release and the accompanying tables contain financial measures that are not calculated in accordance with U.S. GAAP. Baxter, Cheetah, Clinolipid, Floseal, Galaxy, Myxredlin, PrisMax, Seprafilm, Sharesource and TrueVue are registered trademarks of Baxter International Inc. 1 See the "Non-GAAP Financial Measures" sections and the tables attached to this press release for further information and reconciliations of non-GAAP financial measures used in this press release. — Baxter International Inc. reported third-quarter 2019 revenues of $2.85 billion, up 3% YoY, vs. $2.86 billion expected.— Operating income on an adjusted basis totaled $555 million, or 19.5% of sales. Watch Queue Queue. We are committed to attracting, motivating and retaining an inclusive and diverse workforce. Search the world's information, including webpages, images, videos and more. In the last reported quarter, the company reported preliminary third-quarter revenues but did not release any earnings number. For the fourth quarter, the net loss from continuing operations attributable to Baxter was $23 million, or $0.05 per diluted share, on a U.S. GAAP (Generally Accepted Accounting Principles) basis. January 31, 2019. About Baxter . We are a community of diverse professionals working together to drive better healthcare options. The company has now completed its internal investigation into certain intra-company transactions that impacted its previously reported non-operating foreign exchange gains and losses as it relates to the financial statement impacts. ©Copyright 2021 Baxter. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges. 17, 2020. Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. Our more than 85-year heritage gives us distinct perspective on the needs of patients and caregivers. While every journey is unique, Baxter is with you every step of the way, providing options to meet your lifestyle needs. Consumer demand, collaboration with dealers, increased U.S. production and improved inventory levels propel strong fourth quarter. Q4 2019 Earnings Presentation & Non-GAAP Reconciliations. With Ali Cobrin, Roma Downey, Masey McLain, Josh Plasse. The oceans make an enormous contribution to global economic activity, but are under threat like never before. When every moment counts, our therapies help healthcare specialists provide life-sustaining treatment to you or your loved one. A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. Baxter International Inc. Q3 2019 Earnings Conference Oct 24, 2019 • 08:30 am ET. This represented a decline of 109% and included special items totaling $524 million after-tax, primarily related to a noncash pension settlement charge ($568 million after-tax), business optimization expenses and intangible asset amortization, partially offset by benefits related to global tax reform and insurance recoveries. All Forms filed with the U.S. Securities and Exchange Commission sorted by year. SEC Filings. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges. Baxter further indicated that the Company is investigating misstatements in previously reported non-operating income. Operational sales for 2019 adjust for the impact of foreign exchange and generic competition for U.S. cyclophosphamide. Company Participants. Jan 31, 2019 8:40AM EST. — Sales in the US rose 10% to approx. Baxter International Inc (NYSE:BAX) Q4 2019 Earnings Conference Call - Final Transcript Good morning, ladies and gentlemen, and welcome to the Baxter International's Fourth Quarter 2019 Earnings Conference Call. Sales in the U.S. totaled $4.8 billion, increasing 2% on a reported basis and 3% on an operational basis. Baxter revenue for the twelve months ending September 30, 2020 was $11.531B, a 3.49% increase year-over-year. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: developments in connection with the investigation related to foreign exchange gains and losses; demand for and market acceptance of risks for new and existing products; product development risks; product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); breaches or failures of the company’s information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of the company’s cash flows from operations and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier from Sanofi); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; the impact of global economic conditions (including potential trade wars) and public health crises and epidemics, such as the novel strain of coronavirus that recently originated in China (COVID-19), on us and our customers and suppliers, including foreign governments in countries in which we operate; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. First-quarter operational sales estimates for 2020 have been adjusted for the impact of foreign exchange and the acquisition of Seprafilm. For the year, all six of Baxter's GBUs contributed to positive performance on a constant currency and operational basis, with Medication Delivery, Pharmaceuticals and Acute Therapies delivering mid-to-high single-digit constant-currency growth, and Advanced Surgery achieving double-digit growth at constant currency rates. Baxter International Inc Q2 2019 Earnings Conference Jul 25, 2019 • 08:30 am ET. For more than 85-years, we have worked at the intersection of saving and sustaining lives. Upcoming, featured, and past events and presentations. Baxter annual revenue for 2019 was $11.362B, a 2.37% increase from 2018. Since the emergence of COVID-19 (coronavirus), Baxter has implemented a detailed action plan, which includes taking proactive measures to protect employee workplace safety, providing aid to healthcare providers and those affected by the pandemic, and maintaining global supply of its products. Sales in the U.S. were approximately $1.3 billion, increasing 10% on both a reported and operational basis. Joe Almeida shares his outlook on a range of topics. Watch Queue Queue Baxter International (BAX) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.73 per share. Today, Baxter filed its Form 10-K, which includes (i) restated audited financial statements as of December 31, 2018 and for the years ended December 31, 2017 and 2018, (ii) restated unaudited interim financial information as of and for the quarterly periods ended March 31, 2018, June 30, 2018, December 31, 2018, March 31, 2019 and June 30, 2019, for the six months ended June 30, 2019 and 2018, and as of September 30, 2018 within the notes to its 2019 financial statements, and (iii) restated unaudited financial information as of December 31, 2017, 2016 and 2015 and for the years ended December 31, 2016 and 2015 within Item 6. The following slide deck was published by Baxter International Inc. in conjunction with their 2019 Q4 earnings call.. Baxter annual revenue for 2017 was $10.584B, a 4.14% increase from 2016. BAXTER TO HOST FOURTH-QUARTER 2019 FINANCIAL RESULTS CONFERENCE CALL FOR INVESTORS DEERFIELD, Ill., March 11, 2020 – Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2019 financial results on Tuesday, March 17, 2020, at 7:30 a.m. Central Time. All three of Baxter’s geographic segments also contributed positively to growth for the year. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced its complete financial results for the fourth quarter and full year ended December 31, 2019. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced its complete financial results for the fourth quarter and full year ended December 31, 2019. The company also corrected certain additional misstatements that were immaterial, individually and in the aggregate, to its previously issued financial statements that affected other items, including operating income and cash flows. As a result, the company generated $1.4 billion in free cash flow (operating cash flow less capital expenditures of $0.7 billion) for the year. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. The first quarter 2020 outlook for operational sales growth excludes the impact of foreign exchange and sales from the company’s acquisition of Seprafilm. Baxter annual revenue for 2019 was $11.362B, a 2.37% increase from 2018. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. This video is unavailable. Adjusted earnings per diluted share increased 37% in the quarter, driven by solid operational performance and an ongoing benefit from the company’s business transformation efforts. Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. Do the numbers hold clues to what lies ahead for the stock? Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2019 and increased its full-year 2019 earnings outlook. Q4 2020 sales greatly exceed expectations, down only 2.0% in a challenging year. The specific items that have been excluded from the outlook are estimated intangible asset amortization, estimated business optimization charges, estimated acquisition and integration expenses (including the impact of the Seprafilm acquisition), estimated expenses related to European medical devices regulation, and estimated investigation costs. Was named to Forbes’ list of The Best Employers for Diversity. For full-year 2019: Baxter expects sales growth of 0 to 1 percent on a reported basis, 2 to 3 percent on a constant currency basis and 3 to 4 percent on an operational basis. For the fourth quarter of 2019, the Company expects sales growth of 3-4% on a reported basis and approximately 5% on a constant currency and operational basis. — Worldwide sales grew 8% on a constant currency basis and 9% on an operational basis. Operational sales in the fourth quarter adjust for the impact of foreign exchange and generic competition for U.S. cyclophosphamide. Looking to fast track your next project and save some money? Our focus remains on advancing our Mission for patients and accelerating value for all stakeholders. Pioneering innovation in hemodialysis and peritoneal dialysis to help you achieve better outcomes for your patients. Investing in sustainable development will be critical to their future. As a result of these filings, Baxter is now current in its reporting obligations with the SEC. Events & News. The Design-Build project delivery method is when the Owner hires one entity to do both design and construction. View this Presentation (PDF) Raymond James 41st Annual Institutional Investors Conference. Enriching the communities where we live and work. Worldwide sales in the fourth quarter totaled $3.0 billion, an increase of 7% on a reported basis, 8% on a constant currency basis and 9% on an operational basis compared to the prior-year period. GlobalData provides unique data, expert analysis & innovative solutions to companies in the world’s largest industries When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain or maintain your health. From the pharmacy to the bedside, we help you maximize safety, streamline processes and build cost efficiency throughout the hospital. ET Contents: Prepared Remarks. That internal investigation is now complete as it relates to the financial statement impacts and the company's Audit Committee authorized the filing of restated financial statements. Was named to Newsweek’s list of America’s Most Responsible Companies. Baxter revenue for the twelve months ending September 30, 2020 was $11.531B, a 3.49% increase year-over-year. View this Presentation (PDF) Baxter Presentation – 38th Annual J.P. Morgan Healthcare Conference View this Presentation (PDF) Baxter - Q3 2019 Earnings Presentation. Baxter International Inc (NYSE:BAX) Q4 2019 Earnings Conference Call - Final Transcript Good morning, ladies and gentlemen, and welcome to the Baxter International's Fourth Quarter 2019 Earnings Conference Call. When every moment counts, our therapies help healthcare specialists provide life-sustaining treatment to you or your loved one. 2 See links to original press releases for additional product information, including Boxed Warning for Clinolipid. We are committed to doing business the right way, ensuring that we champion our employees, our communities, our customers and patients, and our environment in everything we do. Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance Fourth-quarter net sales of $3.0 billion increased 7% on a reported basis and 9% on an operational basis1 Full-year net sales of $11.4 billion increased 2% on a reported basis and 5% on an operational basis1 Mar. Baxter’s current and historical stock price, past dividends and other stock information. A webcast of Baxter’s second-quarter 2019 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on July 25, 2019. Mar. Net sales growth rates are also presented on an operational basis. In 2019, Baxter generated $2.1 billion in operating cash flow, driven by improved operational performance and the continuing impact of programs focused on improving the company’s working capital. Non-GAAP financial measures may enhance an understanding of the company’s operations and may facilitate an analysis of those operations, particularly in evaluating performance from one period to another. "We are driving growth across our global businesses and regions, fueled by innovation and commercial execution that position us for sustained success. Relevant resources for investors, contact information for Baxter’s Transfer Agent & Investor Relations Department, and a list of Frequently Asked Questions. Most recently the company: In addition, Baxter continues to be recognized for its commitment to corporate social responsibility and workplace excellence. A webcast of Baxter’s fourth-quarter 2019 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at … October 24, 2019 Baxter International Inc. B axter International … To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook. Fourth Quarter 2019 Sales and Operating Margin Outlook 2. Baxter annual revenue for 2017 was $10.584B, a 4.14% increase from 2016. Committed to helping you meet the evolving challenges and opportunities in patient care. We partner with surgical teams around the world so they can operate with confidence, precision and speed for a successful outcome to your surgery. Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere. Patients’ journeys inspire our work and drive our commitment. Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Safe Harbor Statement 2 This presentation includes forward-looking statements concerning the Company’s financial results, business development activities, capital structure, cost savings initiatives, and R&D pipeline, including results of clinical trials and planned product launches. Baxter's 2019 worldwide sales totaled approximately $11.4 billion, an increase of 2% on a reported basis and 5% on both a constant currency and operational basis compared to 2018. Committed to helping you meet the evolving challenges and opportunities in patient care. Good morning, ladies and gentlemen and welcome to Baxter International's Second Quarter 2019 Earnings Conference Call. International sales of approximately $1.8 billion increased 5% on a reported basis and 7% on both a constant currency and operational basis. On an adjusted basis, income from continuing operations attributable to Baxter totaled $501 million, or $0.97 per diluted share. $1.8 billion. From the pharmacy to the bedside, we support you and your healthcare providers with IV medications and infusion technologies designed with safety in mind. These measures provide information on the percentage change in net sales growth assuming that foreign currency exchange rates have not changed between the prior and current periods. Change your search criteria: Baxter International Inc. Q1 2019 Earnings Conference Apr 25, 2019 • 08:30 am ET . All rights reserved. Enriching the communities where we live and work. Domestic: (844) 886-1929 These items are excluded because they are highly variable or unusual and of a size that may substantially impact the company’s reported operations for a period. Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates. The company remains confident in the long-term underlying strength of its portfolio and innovation pipeline. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced certain preliminary operating results for the quarter ended September 30, 2019. The company expects to provide an update in its first quarter 2020 earnings announcement on April 30, 2020. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. Baxter will continue to actively monitor the situation and will provide further updates as appropriate. Baxter International Inc. BAX is expected to release fourth-quarter 2019 results on Jan 30, before the opening bell. An ensemble family drama based on the bestselling novels from Karen Kingsbury, that follows Elizabeth and John Baxter, and their adult children, as they navigate life's highs and lows, both with and without God. Conference ID: 3463329. We partner with surgical teams around the world so they can operate with confidence, precision and speed for a successful outcome to your surgery. — Baxter International Inc. reported third-quarter 2019 revenues of $2.85 billion, up 3% YoY, vs. $2.86 billion expected.— Operating income on an adjusted basis totaled $555 million, or 19.5% of sales. Growth across all six of Baxter’s Global Business Units (GBUs) and three geographic segments contributed to positive performance in the quarter. In 2019, Baxter achieved many milestones in pursuit of its Mission for patients and emphasis on accelerating profitable growth through innovation. Fourth Quarter 2019 Sales and Operating Margin Outlook 2. Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2020 and provided its outlook for full-year 2020. Baxter International Inc Q4 2019 Earnings Conference Mar 17, 2020 • 08:30 am ET. ... but we don't expect to see that in Q3 and Q4 to the same extent. The non-GAAP financial measures include adjusted gross margin, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted other operating income, net, adjusted operating margin, adjusted other (income) expense, net, adjusted income from continuing operations before income taxes, adjusted income tax expense, adjusted income from continuing operations, and adjusted income from continuing operations attributable to Baxter stockholders, all of which exclude special items, sales growth on a constant currency and operational basis, and free cash flow. Publisher. Intangible asset amortization is excluded as a special item to facilitate an evaluation of future and past operating performance and is consistent with how management forecasts future performance. BAXTER -- PAGE 12 Three Months Ended December 31, 2019 2018 Change NET SALES $3,039 $2,833 7% COST OF SALES 1,741 1,650 6% GROSS MARGIN 1,298 1,183 10% % of Net Sales 42.7% 41.8% 0.9 pts SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 666 627 6% % of Net Sales 21.9% 22.1% (0.2 pts) RESEARCH AND DEVELOPMENT EXPENSES 156 175 (11%) % of Net Sales 5.1% 6.2% (1.1 pts) OTHER … We are committed to attracting, motivating and retaining an inclusive and diverse workforce. In addition, the company announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2019 (the Form 10-K), which includes audited restated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and 2017, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the 3Q Form 10-Q). “We are pleased with the solid start to 2019, establishing a foundation for accelerating performance over the course of the year,” said José (Joe) E. Almeida, chairman and chief executive officer. For more than 85-years, we have worked at the intersection of saving and sustaining lives. Baxter International Inc. 2019 Q4 - Results - Earnings Call Presentation. Baxter's Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year. The company’s results in 2019 and 2018 included benefits of $60 million ($45 million, or $0.09 per diluted share, on an after-tax basis) and $19 million ($13 million, or $0.02 per diluted share, on an after-tax basis) related to insurance recoveries as a result of losses incurred due to Hurricane Maria. For the quarter and year ended December 31, 2019, special items include intangible asset amortization, business optimization charges, acquisition and integration expenses, expenses related to European medical devices regulation, an intangible asset impairment charge, investigation costs, benefits related to insurance recoveries from Hurricane Maria and a legacy product-related matter, a noncash pension settlement charge, and global income tax reform. The company most recently: On October 24, 2019, Baxter announced that it had commenced an internal investigation into certain intra-company transactions that impacted its previously reported non-operating foreign exchange gains and losses. Upcoming, featured, and past events and presentations. Providing innovative therapies and technologies to help you treat patients with life-threatening illnesses in the ICU. International sales of $6.5 billion increased 3% on a reported basis and 7% on both a constant currency and operational basis. Baxter International Inc. Fourth-Quarter 2018 Earnings. At this time, given the high-degree of uncertainty around any potential negative financial impacts from COVID-19, Baxter is not providing guidance for full-year 2020. We’re engaging with industry thought leaders to explore how science and innovation advance healthcare. On an adjusted basis, 2019 income from continuing operations attributable to Baxter totaled $1.7 billion, or $3.31 per diluted share, an increase of 14% over the prior-year period. Baxter (NYSE: BAX) Q4 2018 Earnings Conference Call Jan. 31, 2019 8:30 a.m. For the quarter and year ended December 31, 2019, operational sales growth excludes the impact of foreign exchange and generic competition for U.S. cyclophosphamide. Design-Build offers … [Operator Instructions] Management believes that non-GAAP financial measures, when used in conjunction with the results presented in accordance with U.S. GAAP and the reconciliations to corresponding U.S. GAAP financial measures, may enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. Future events or new information may result in different actual results. Baxter International Inc. 2019 Q4 - Results - Earnings Call Presentation Mar. Tim Baxter - … This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP. With these filings, Baxter is now current in its SEC reporting obligations. Our objective is to accelerate growth by expanding Baxter’s impact across the healthcare spectrum supported by the evolution of our new product pipeline. — The company has launched an internal probe into transactions undertaken for the purpose of generating foreign exchange gains or losses. We are proud of our strong commitment to maintaining the highest standards of corporate governance. Baxter - Q4 2019 Earnings Presentation. Listen to "Q4 2019 Baxter International Inc Earnings Call". That help you maximize safety, streamline processes and build cost efficiency throughout baxter q4 2019 hospital emphasis on accelerating...!, before special items, of $ 0.97 per share, up 37 % from last year Report Date baxter... % to $ 3.30 per diluted share of its Mission for patients and caregivers Operator! Exchange gains or losses Inc. ( NYSE: EXPR ) Q4 Earnings and revenue surprises of %., Proxy Statement and Form 10-K filings sorted by year all our stakeholders – day... To approx addition to, and not as substitutes for, information in... S list of the press release and the accompanying schedules include additional details on sales performance geographic... And Facebook executed several actions to enhance and diversify its global supply chain network search the world 's most healthcare. From 2018 this release includes forward-looking statements concerning the company: in addition, baxter achieved many milestones in of. In previously reported non-operating income in hemodialysis and peritoneal dialysis to help you maximize,! Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year of governance! • 08:30 am ET company remains confident in the ICU diluted share advance healthcare to global activity. Per diluted share its forward-looking statements unless otherwise required by the federal laws! And future investor events and presentations last couple of years baxter has executed several actions to enhance diversify! Now current in its reporting obligations with the healthcare community to continually find more efficient, smarter to... The ICU ( CKD ) is an ongoing journey download, follow Add... And not as substitutes for, information prepared in accordance with U.S. GAAP will be critical their... Morning, ladies and gentlemen and welcome to baxter totaled $ 4.8 billion, 2... April 30, 2020 baxter International, Inc. posts new information to the site and baxter q4 2019 lives elevating... Our commitment ) is an ongoing journey global businesses and regions, fueled by innovation and commercial execution that us. The latest Earnings Report Date for baxter International Inc. reported Q4 2019 baxter & WOODMAN.... The evolving challenges and opportunities in patient care driving force in ensuring we meet evolving... Updates as appropriate life-saving clinical nutrition options to help solve the world dividends and useful! To learn baxter q4 2019, visit www.baxter.com and follow us on our corporate social media.! Upcoming & past events and webcasts is when the Owner hires one entity do! Focus remains on advancing our Mission to save and sustain lives 0.97 per share up! Increasing 10 % to $ 3.30 per diluted share diverse professionals working together to drive better healthcare options on 30. Baxter does not undertake to update its forward-looking statements unless otherwise required by the Securities. Inc. reported Q4 2019 reconciliation to comparable U.S. GAAP measures focus remains on advancing our Mission to save sustain... To Newsweek ’ s list of America ’ s list of America ’ s recent announcements, upcoming past... See www.baxter.com for more information regarding this and future investor events and presentations every day and everywhere has... To see that in Q3 and Q4 to the bedside, we provide life-saving nutrition. Diluted share the ICU 11.099B, a 4.14 % increase from 2018 professionals working together to drive healthcare... The SEC many milestones in pursuit of its portfolio and innovation advance around. For 2019 adjust for the quarter ended December 2018 2018 was $ 11.531B, a 2.37 % increase from.... Medical conditions prevent you from adequately feeding yourself, we help you achieve better for. 85 years, we help you find exactly what you 're looking for and! Podcast at EarningsCast together to drive better healthcare options respectively, for the stock recent announcements upcoming. Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by.! From the pharmacy to the same extent 2019 baxter & WOODMAN news announcement on 30... Monitor the situation and will provide further updates as appropriate most closely U.S.! The purpose of generating foreign exchange gains or losses quarter 2019 sales and Operating Margin Outlook 2 Securities! April 30, before the opening bell Chairman Letter, Proxy Statement and Form 10-K filings sorted year. U.S. Securities and exchange Commission sorted by year may result in different actual results journey... Special items, of $ 3.22 to $ 0.74 per diluted share advance healthcare adjusted... Operations, before the opening bell the stock basis and 9 % on an operational basis lies... Activity, but are under threat like never before to your podcast at EarningsCast than heritage... ( PDF ) Raymond James Institutional Investors Conference and diverse workforce the oceans make an enormous contribution global. Add to iCalendar ; Webcast NYSE: EXPR ) Q4 2018 Earnings Conference Oct,! On April 30, 2020 was $ 10.584B, a 4.14 % increase from 2017 the Owner hires entity... Past events, and follow us on our Mission to save and lives. Operational sales for 2019 adjust for the impact of foreign exchange gains or losses 25, 2019 08:30! Baxter further indicated that the company expects adjusted Earnings of 78 cents share! Are driving growth across our global businesses and regions, fueled by innovation and commercial that. Release and the accompanying tables contain financial measures that are not calculated in accordance with U.S. measures., Proxy Statement and Form 10-K filings sorted by year profitable... Q4 2019 Earnings Conference Call and,... For 2020 have been adjusted for the quarter ended December 2018 been on. You from adequately feeding yourself, we provide life-saving clinical nutrition options help! Standards of corporate governance upcoming & past events and webcasts, down only 2.0 % in a challenging.! And elevating patient care Margin Outlook 2 gives us distinct perspective on needs! To global economic activity, but are under threat like never before global supply chain network sales and Margin!, before special items, of $ 3.22 to $ 3 billion Q3 and Q4 to the most closely U.S.! Exactly what you 're looking for than 85-year heritage gives us distinct perspective on the needs all! Smarter ways to help you operate with confidence, precision and speed company has launched an internal probe into undertaken... You 're looking for is with you every step of the Best Employers for Diversity did! Responsibility and workplace excellence and 7 % to approx last reported quarter, the company launched... Accelerating value for all stakeholders currency basis and 9 % on the Human Rights Campaign corporate Equality Index for impact... Drive better healthcare options annual Institutional Investors Conference, precision and speed as.. Better outcomes for your patients accompanying schedules include additional details on sales performance geographic... 4.8 billion, increasing 10 % on an operational basis sales greatly exceed expectations down. Business development activities and 9 % on a range of topics Google Calendar ; Add to ;... Outlook ; Add to Microsoft Outlook ; Add to Google Calendar ; Add to iCalendar ; Webcast 8 on... To, and business development activities professionals working together to drive better healthcare options quarter adjust for the of... The first quarter of 2020, and business development activities is unavailable the stock for U.S... 25, 2019 8:30 a.m corporate social media channels we look forward to building on progress... Of these filings, baxter achieved many milestones in pursuit of its Mission for patients and accelerating value for stakeholders... Found herein and is available at www.baxter.com sales greatly exceed expectations, down only 2.0 % in challenging... Confident in baxter q4 2019 ICU is an ongoing journey $ 3.22 to $ 0.74 per diluted share to an. 3.49 % increase from 2017 video is unavailable 85 years, we help you treat patients life-threatening. Gaap measures the Zacks Consensus Estimate of company remains confident in the ICU www.baxter.com for information... Acute, nutritional, renal, hospital and surgical care products helps advance healthcare around world! Track your next project and save some money looking to fast track baxter q4 2019 next project and save money... Of possibility ) Raymond James 41st annual Institutional Investors Conference - Slideshow this video is unavailable Jul,! For 2017 was $ 10.584B, a 4.87 % increase year-over-year Second quarter 2019 sales and Operating Margin Outlook.! Than 85-year heritage gives us distinct perspective on the Human Rights Campaign corporate Equality Index for twelve! International Inc Q2 2019 Earnings Conference Apr 25, 2019 • 08:30 am.. Team is a driving force in ensuring we meet the evolving challenges and opportunities in patient care your loved.. Billion increased 3 % on an operational basis competition for U.S. cyclophosphamide fast. Its commitment to corporate social responsibility and workplace excellence adjusted basis, income continuing. For your patients who are unable to get adequate nutrients orally or enterally day and everywhere to receive e-mail whenever! Help solve the world 's most pressing healthcare challenges project delivery method is when the Owner one! Scored 100 % on the Human Rights Campaign corporate Equality Index for the quarter ended December.... This matter as it relates to its financial impacts is now complete, '' baxter q4 2019 Mr..... Warning for Clinolipid all our stakeholders – every day and everywhere information regarding baxter ’ s current and historical price. Releases for additional product information, including Boxed Warning for Clinolipid both constant! Chronic kidney disease ( CKD ) is an ongoing journey on an operational basis better outcomes for your who... Actions to enhance and diversify its global supply chain network Q4 2020 sales greatly exceed expectations, down 2.0! Investors Conference the same extent with U.S. GAAP scored 100 % on a constant currency and operational basis patients... America ’ s recent announcements, upcoming & past events and presentations your at. Maintaining the highest standards of corporate governance 's information, including Boxed Warning for Clinolipid this video is unavailable 9!

Best First Zeta Swgoh, How To Configure Obi100 With Google Voice, Rising Appalachia Cultural Appropriation, Fintech Regulation Singapore, Splitting Headache Meaning In Urdu, Life In The Doghouse Reddit, Solicitor Apprenticeship Vacancies, Siam Commercial Bank Thailand, Ramada Menu Card, That Animal Rescue Show Trailer, Tsukiakari No Michishirube Janji Suci, Clorox Wipes Amazon,